Published Studies Related to Campral (Acamprosate)
Efficacy of acamprosate for alcohol dependence in a family medicine setting in
the United States: a randomized, double-blind, placebo-controlled study. 
glutamyltransferase level (normal or high)... CONCLUSIONS: This clinical trial did not find evidence of efficacy for
A randomized, double-blind, placebo-controlled clinical trial of acamprosate in
alcohol-dependent individuals with bipolar disorder: a preliminary report. 
co-occurring bipolar disorder and active alcohol dependence... CONCLUSIONS: Acamprosate was well-tolerated, with no worsening of depressive or
Acamprosate for alcohol dependence: a sex-specific meta-analysis based on
individual patient data. 
alcohol dependence... CONCLUSIONS: This sex-specific IPD meta-analysis provides evidence that
The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. [2011.11.01]
AIMS: The aim of this randomized, controlled, multisite trial was to evaluate the efficacy of combined treatment with integrative behaviour therapy (IBT) and acamprosate on drinking behaviour in detoxified alcohol-dependent patients... CONCLUSION: The results suggest that the combination of acamprosate and IBT is not more effective than treatment with either IBT or acamprosate alone. However, the two acamprosate conditions differed in success rate by about 10%, which might constitute a clinically relevant though statistically non-significant effect. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. [2011.10]
In alcoholism, both relapse to alcohol drinking and treatment response are suggested to be genetically modulated. This study set out to determine whether the top 15 single nucleotide polymorphisms (SNPs) of a recent genome-wide association (GWA) and follow-up study of alcohol dependence are associated with relapse behavior and pharmacological treatment response in 374 alcohol-dependent subjects who underwent a randomized, double-blind, placebo-controlled trial with acamprosate, naltrexone or placebo...
Clinical Trials Related to Campral (Acamprosate)
Acamprosate: Genes Associated With Response [Recruiting]
In 2004, acamprosate was approved in the U. S. for abstinence maintenance, by decreasing
craving, in alcoholic patients who have undergone detoxification. while a new anti-craving
drug was encouraging, only 36. 1% of the subjects treated with acamprosate remained abstinent
for 6 months. Having the ability to identify treatment responsive individuals would have a
major impact on the use of acamprosate.
Biomarker Study of Acamprosate in Schizophrenia [Recruiting]
NMDA receptors are brain receptors that are stimulated by glutamate. Poorly functioning
NMDA receptors are thought to be involved in the pathology of schizophrenia. This
hypothesis is based on the observation that PCP, which blocks the NMDA receptor, produces
symptoms and cognitive impairments similar to schizophrenia. Efforts to enhance the
function of the NMDA receptor with glycine and D-cycloserine have met with limited success.
An alternative approach would be to use the drug acamprosate.
Acamprosate, FDA-approved for maintenance of sobriety after detoxification from alcohol,
seems to act through modulation of the NMDA receptor. In the lab, acamprosate has been
noted to act as an antagonist when the NMDA receptors are maximally stimulated but as an
agonist when NMDA receptor stimulation is minimal. This "smart drug" action makes
acamprosate appealing for use in schizophrenia. If acamprosate works as a smart drug in
patients, then we would predict that it would enhance the function of NMDA receptors in
schizophrenia and improve cognition and the symptoms of the illness. Additionally,
acamprosate seems to modulate the NMDA receptor in novel ways distinct from glycine and
We will also see if the response to acamprosate differs based on whether participants do or
do not have a past history of alcohol use disorders.
Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence [Active, not recruiting]
Acamprosate in Youth With Fragile X Syndrome [Recruiting]
Fragile X syndrome (FXS) is the most common inherited form of developmental disability. FXS
is inherited from the carrier parent, most often the mothers. FXS is associated with severe
interfering behavioral symptoms which include anxiety related symptoms, attention deficit
hyperactivity, and aggressive behaviors. Approximately 25-33% of individuals with FXS also
meet criteria for autistic disorder. The hypothesis of this study is that treatment with
acamprosate will reduce inattention/hyperactivity, language impairment, irritability, social
deficits, and cognitive delay in youth with FXS. The purpose of this study is to
investigate the effectiveness and tolerability of acamprosate in youth with Fragile X
Syndrome and to assess the potential psychophysiological differences between FXS and autism
Acamprosate in Alcoholics With Comorbid Anxiety or Depression [Recruiting]
The primary objective of this study is to compare the safety and efficacy of acamprosate
versus placebo in the treatment of alcohol dependence in adults with co-occurring mood or
anxiety disorders (specifically, depression (MDE), generalized anxiety disorder (GAD) or
social anxiety disorder). Secondary objectives are to evaluate the effect of acamprosate
treatment on mood and anxiety disorders.
This is a randomized, double-blind, placebo-controlled trial evaluating acamprosate in the
treatment of alcohol dependence in adult outpatients with concurrent mood and/or anxiety
disorders. The active study phase will be 12 weeks in duration. There will be a two-week
screening period, followed by 12 weeks of study medication and a follow-up assessment at 14
weeks from randomization.
A total of 90 (30 per site) men and women aged 18-60 years who have a current diagnosis of
alcohol dependence as well as a current DSM-IV diagnosis of either MDE, GAD and/or social
anxiety will be recruited to participate in this study. Only those individuals whose
psychiatric disorders are stable will be randomized to acamprosate or placebo. Three sites
will participate in this trial.
Eligible participants will be randomly assigned to receive either acamprosate or matching
placebo for 12 weeks.
The primary efficacy outcome measure will be cumulative days abstinent as measured by
Reports of Suspected Campral (Acamprosate) Side Effects
Intentional Drug Misuse (4),
Foetal Alcohol Syndrome (3),
Colitis Microscopic (2),
Ejaculation Delayed (2),
Suicide Attempt (2),
Confusional State (1), more >>